Epstein-Barr Virus (EBV/HHV-4) Research Reagents — Antibodies & Recombinant Proteins

Epstein-Barr virus (EBV, also designated HHV-4) is an enveloped, double-stranded DNA gammaherpesvirus (~170 kb genome) that infects over 95% of the global adult population. EBV establishes lifelong latency in B lymphocytes and is etiologically linked to multiple malignancies — Burkitt lymphoma, nasopharyngeal carcinoma (NPC), Hodgkin lymphoma, post-transplant lymphoproliferative disease (PTLD), and gastric carcinoma — as well as multiple sclerosis (MS). Key envelope glycoproteins include gp350 (CR2/CD21 attachment), gB (fusogen), gH/gL (fusion trigger), and gp42 (B-cell tropism switch via HLA class II binding). Latency-associated proteins — EBNA1, EBNA2, LMP1, LMP2A — drive oncogenic transformation and are targets for therapeutic antibodies and cellular immunotherapy.

Research Use OnlyNot for diagnostic or therapeutic use.

abinScience offers a comprehensive EBV/HHV-4 reagent portfolio covering all major surface glycoproteins (gp350, gB, gH/gL, gp42), latency-associated oncoproteins (LMP1, EBNA1), and lytic-cycle antigens (BZLF1/Zta, BMRF1, EA-D) — including InVivoMAb neutralizing antibodies, recombinant proteins in multiple tag formats and complexes (gH/gL dimer, gH/gL/gp42 trimer), and polyclonal detection antibodies. Manufactured by AtaGenix Laboratories (ISO 9001 & ISO 13485). Contact us for antibody pairs and bulk orders.

Envelope Glycoproteins — Entry & Neutralization Targets

gp350/gp340 (BLLF1/MA) — Primary Attachment Protein
gp350 binds complement receptor CR2/CD21 on B cells and is the immunodominant target for virus-neutralizing antibodies. gp350 is the lead antigen in Moderna's EBV vaccine candidate (mRNA-1189). Available: recombinant gp350 proteins (C-His VK622011, N-His VK622012), anti-gp350 pAb (VK622014), and recombinant anti-gp350 antibodies including the well-characterized neutralizing clone 72A1 (VK622013) and clones SAA2664 (VK622033) and SAA2665 (VK622043).

Glycoprotein B (gB/BALF4)
gB is the class III fusion protein required for viral entry into all cell types. Anti-gB neutralizing antibodies block post-attachment membrane fusion. Available: InVivoMAb antibodies Iv0133 (VK799010) and Iv0134 (VK799020), recombinant antibodies 1D8 (VK799013), CL55 (VK799023), and AMMO5 (VK799033); recombinant gB proteins in three formats (C-His VK799011, N-His VK799012, C-Fc VK799021); and anti-gB pAb (VK799014).

gH/gL Complex & gH/gL/gp42 Trimer
The gH/gL heterodimer triggers membrane fusion and is the scaffold for gp42, which switches EBV tropism to B cells via HLA class II. abinScience uniquely offers pre-formed complexes for structural and functional studies: gH/gL dimer (VK598021), gH/gL/gp42 trimer (VK598011), and gH/gp42 complex (VK598031). Anti-gH/gL neutralizing antibodies: CL40 (VK598013), CL59 (VK598023), 769B10 (VK598033), AMMO1 (VK598043), and E1D1 (VK729013). Individual gH proteins: C-Strep (VK598041), C-His (VK598051), N-His (VK598012), plus anti-gH pAb (VK598014).

Glycoprotein 42 (gp42)
gp42 binds HLA class II and is essential for B-cell tropism. Anti-gp42 antibodies specifically block B-cell infection without affecting epithelial entry. Available: recombinant antibodies SAA2098 (VK491013) and SAA2099 (VK491023); recombinant gp42 proteins (C-His VK491011, N-His VK491012); and anti-gp42 pAb (VK491014).

gL & Other Envelope Proteins
gL (light chain of gH/gL complex): recombinant protein N-GST&C-His (VK598022) and anti-gL pAb (VK598024). BILF2 (glycoprotein function unknown): recombinant protein N-His (VK174012).

Latency & Lytic Cycle Antigens — Oncology & Diagnostics

LMP1 (BNLF1) — Major EBV Oncoprotein
LMP1 is a constitutively active TNF receptor homolog that drives NF-κB, JAK/STAT, and PI3K signaling — the primary EBV oncoprotein responsible for B-cell transformation. LMP1 is expressed in NPC, Hodgkin lymphoma, and PTLD and is a therapeutic target. abinScience offers the most extensive anti-LMP1 antibody panel available, with 11 recombinant clones recognizing distinct epitopes: A3H5, B10E7, H11F6, B10B7, B2A4, B8, G5, A4, F5, E2, and H3 — enabling epitope mapping, functional blocking studies, and IHC/WB detection in tumor biopsies.

EBNA1 (BKRF1)
EBNA1 is the only viral protein expressed in all latency programs and is essential for episome maintenance in latent infection. EBNA1 is a target for therapeutic intervention (EBNA1 dimerization inhibitors) and a serological marker. Available: recombinant antibodies 3D4 (VK686013) and 16D2 (VK686023), recombinant EBNA1 protein N-His (VK686012), and anti-EBNA1 pAb (VK686014).

BZLF1/Zta & BMRF1 — Lytic Reactivation Markers
BZLF1 (Zta/ZEBRA) is the master lytic switch transactivator — its expression initiates EBV reactivation from latency. BMRF1 (EA-D) is an early-antigen diffuse component and traditional serological marker for active lytic infection. Available: BZLF1 protein N-GST&C-His (VK536012), anti-BZLF1 pAb (VK536014), BMRF1 protein N-His (VK074012), and anti-BMRF1 pAb (VK074014).

Frequently Asked Questions

Which antibodies are recommended for EBV neutralization studies?
EBV neutralization requires targeting both B-cell and epithelial cell entry pathways. For B-cell entry: anti-gp350 clone 72A1 blocks CR2 attachment, and anti-gp42 antibodies (SAA2098) block HLA class II-dependent entry. For epithelial cell entry: anti-gH/gL antibodies (AMMO1, 769B10) and anti-gB InVivoMAbs (Iv0133, Iv0134) block fusion.

Do you offer pre-formed gH/gL and gH/gL/gp42 protein complexes?
Yes — this is a key differentiator. We provide co-expressed, purified complexes: gH/gL dimer (VK598021) and gH/gL/gp42 trimer (VK598011), both with dual tags for oriented capture. These pre-formed complexes maintain native conformation for structural studies, vaccine antigen evaluation, and epitope mapping of complex-specific neutralizing antibodies.

Which reagents are most relevant for EBV-associated cancer research?
For tumor biology: our anti-LMP1 antibody panel (11 clones) for IHC/WB detection and functional blocking of NF-κB activation, and anti-EBNA1 antibodies for episome detection. For NPC diagnostics: anti-VCA and EBNA1 recombinant protein (VK686012) as ELISA coating antigen.

Related Herpesvirus Reagents

Explore reagents for related herpesviruses:

HSV-1 (HHV-1) HSV-2 (HHV-2) VZV (HHV-3) EBV (HHV-4) ✓ CMV (HHV-5) Pseudorabies (PRV)